Profit

UK Approval For Seretide MDI: Cipla

PUBLISHED ON: December 27, 2016 | Duration: 7 min, 20 sec

  
loading..
Kedar Upadhye, global CFO of Cipla, says the company has received approval for the Seretide MDI inhaler. This is a market with a $200 million size as Cipla will be the second generics player in the UK market, he adds.
ALSO WATCH
Sensex, Nifty Give Up Early Gains

................................ Advertisement ................................

................................ Advertisement ................................